Condition (MeSH)
Carcinoma, Signet Ring Cell
ClinicalTrials.gov lists 13 trials for Carcinoma, Signet Ring Cell or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 13 trials are tagged with Carcinoma, Signet Ring Cell itself; the rest are tagged with a narrower condition beneath it.
When did Carcinoma, Signet Ring Cell trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2013 | 1 |
| 2010 | 2 |
| 2000 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinoma, Signet Ring Cell trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 3 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 5 |
How many Carcinoma, Signet Ring Cell trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 4 |
| Terminated | 1 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinoma, Signet Ring Cell trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Elucida Oncology | 1 |
| National Cancer Institute (NCI) | 1 |
Which drugs are being tested for Carcinoma, Signet Ring Cell? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| NIVOLUMAB | 2 |
| OXALIPLATIN | 1 |
| ELU001 | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| [68Ga]Ga-FAPI-46 | 1 |
| iv injection of ICG | 1 |
| Talimogene Laherparep 100 Mil Pfu/Ml 1Ml | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Carcinoma, Signet Ring Cell? (40)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer. | Journal of the National Cancer Institute | 2024 | Yes |
| Single-Cell Profiling of Tumor Immune Microenvironment Reveals Immune Irresponsiveness in Gastric Signet-Ring Cell Carcinoma. | Gastroenterology | 2023 | Yes |
| Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis. | Molecular cancer research : MCR | 2023 | Yes |
| Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. | Oncogene | 2022 | Yes |
| Single-bite versus double-bite technique for mapping biopsies during endoscopic surveillance for hereditary diffuse gastric cancer: a single-center, randomized trial. | Endoscopy | 2021 | Yes |
Showing 5 of 40 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.